International Supply Chains: How Foreign Manufacturing Dependence Is Causing Drug Shortages in 2025
Every year, more than 40% of the active ingredients in the pills and injections Canadians rely on come from just two countries: China and India. That’s not a coincidence-it’s the result of decades of cost-cutting decisions that turned global supply chains into fragile, single-threaded pipelines. By 2025, this dependence isn’t just a business risk. It’s a public health emergency. When a factory in Shanghai shuts down for a week, or a port in Mumbai gets backed up, hospitals in Calgary, Toronto, or Vancouver start running low on antibiotics, blood pressure meds, and even insulin. The system was built for efficiency, not resilience. And now, we’re paying the price.
Why Drug Ingredients Are Made Overseas
The reason most drugs aren’t made in North America has nothing to do with skill and everything to do with cost. Making the raw chemical compounds-called active pharmaceutical ingredients (APIs)-requires specialized equipment, strict regulatory controls, and large-scale chemical processing. In the 1990s and 2000s, companies realized they could cut production costs by 60-80% by moving these operations to countries where labor, energy, and environmental regulations were cheaper. China now produces over 70% of the world’s APIs. India handles another 20%, especially for generic drugs. Together, they supply the bulk of medications used in the U.S., Canada, and Europe. This wasn’t a secret. Drugmakers knew what they were doing. But they assumed global trade would stay stable. They didn’t plan for pandemics, trade wars, or climate-driven port closures. Now, with 94% of multinational companies identifying raw material procurement as their biggest supply chain vulnerability, the risks are impossible to ignore.How Supply Chain Disruptions Lead to Drug Shortages
It takes more than one factory to make a single pill. A typical medication might need five or six different chemical ingredients, each sourced from a different supplier. One of those suppliers might be in Vietnam. Another in Germany. But the most critical ones? They’re almost always in China. When China’s ports shut down in 2024 due to labor strikes and extreme weather, it took 50% longer for shipments to reach North America. That delay didn’t just mean slower deliveries. It meant empty shelves. Hospitals rationed antibiotics. Cancer patients got delayed treatments. Diabetics switched to less effective insulin brands because their usual supply ran out. The problem isn’t just delays. It’s concentration. If one facility in Shanghai makes 80% of the world’s metformin (a common diabetes drug), and that facility has a fire, there’s no backup. No alternative supplier. No quick fix. Just a global shortage. According to the U.S. Food and Drug Administration, over 300 drug shortages were reported in 2024 alone. About 60% of those were directly tied to API supply issues. Canada’s Health Department saw similar trends. And it’s not getting better. In 2025, 56% of pharmaceutical companies reported cutting back on new drug launches or delaying product rollouts because they couldn’t guarantee ingredient supply.The Cost of Fixing It
Some companies are trying to fix this. A few are moving production closer to home-what’s called nearshoring. Mexico, for example, is becoming a hotspot for pharmaceutical manufacturing. The country already supplies 15% of Canada’s drug imports. The advantage? Transportation costs drop by 30-40% compared to shipping from Asia. Lead times shrink from 45 days to under 15. And because Mexico is part of the USMCA trade deal, tariffs are low and rules are clear. But it’s not cheap. Labor in Mexico is 15-20% more expensive than in China. Setting up a new API plant costs $200 million or more. And it takes 18 to 24 months just to get permits, build facilities, and get regulatory approval. That’s not a quick fix. It’s a multi-year investment. Other companies are going all-in on multi-shoring. Instead of relying on one supplier in China, they’re now using two or three across different countries. One makes the API. Another handles packaging. A third does quality testing. This approach has cut disruption days by 65% compared to single-source models, according to Procurement Tactics’ 2025 data. But it requires more oversight, more contracts, and more digital tools to track everything. And then there’s automation. Microfactories-small, highly automated plants that can produce niche drugs on demand-are gaining traction. One Canadian firm recently installed a microfactory that can make 10 different antibiotics in the same space. It responds to demand in weeks, not months. But it costs 40% more upfront than a traditional plant. Only big players can afford it.
What’s Holding Back Change
You’d think the solution is obvious: bring manufacturing home. But it’s not that simple. The U.S. and Canada don’t have the chemical infrastructure to replace China overnight. There aren’t enough trained chemists. The factories are aging. The environmental rules are stricter. And wages? Manufacturing labor in North America is 4.8 times more expensive than in China, according to IMD Business School. That’s not a gap you close with goodwill. Plus, there’s inertia. Pharmaceutical companies operate on thin margins. A 5% increase in ingredient costs can wipe out profits. So many still sign long-term contracts with Asian suppliers, even when they know the risks. They’re betting the next disruption won’t be as bad. And then there’s the regulatory maze. Getting a new API facility approved by Health Canada or the FDA takes years. The paperwork is massive. Inspections are brutal. Even if you build the plant, you can’t start making medicine until every step is certified. That’s why only 40% of Asian-based pharma firms have started multi-shoring by mid-2025.What’s Working Right Now
Some companies are getting it right. One Fortune 500 medical device maker switched from relying on a single supplier in China to using dual sources-one in Mexico and one in Poland. They added real-time tracking using IoT sensors and blockchain verification for quality control. Result? On-time delivery jumped to 99.2%. Quality disputes dropped by 65%. And when a typhoon hit the Philippines in early 2025, their supply stayed intact. Another Canadian firm invested in AI-driven forecasting. Instead of ordering raw materials based on guesswork, they now use machine learning to predict demand spikes and supply delays. They cut inventory waste by 22% and avoided three potential shortages last year. Even small players are adapting. A Calgary-based generic drug distributor started keeping 60-day stockpiles of high-risk medications instead of the old 30-day norm. It cost more upfront, but it meant they never ran out during the 2024 shortages. Their customers-small clinics and pharmacies-stayed open. Their reputation stayed strong.
What Needs to Change
Government action is the missing piece. Right now, most countries treat pharmaceutical supply chains like any other industry. They don’t see them as critical infrastructure. But they should. Just like power grids and water systems, medicine needs redundancy, backup plans, and emergency reserves. The U.S. has started. The CHIPS Act and Inflation Reduction Act include funding for domestic API production. Canada’s 2025 National Medicines Strategy now includes a $1.2 billion fund to support local manufacturing and stockpiling. But it’s not enough. We need tax incentives for companies that diversify suppliers. We need faster regulatory pathways for new facilities. We need mandatory minimum stockpiles for essential drugs. And we need to stop pretending this is just a business problem. It’s a health crisis. When a child can’t get their asthma inhaler because the API was stuck in a Chinese port, that’s not a logistics issue. That’s a failure of policy.The Road Ahead
By 2027, global GDP growth might recover to 3.1% if trade tensions ease. But even if they do, the old model won’t come back. The world has seen what happens when supply chains break. Companies won’t go back to single-source dependence. Governments won’t ignore the risks. Consumers won’t accept empty shelves. The future of drug supply chains isn’t about going back to local production. It’s about building smart, distributed networks-mixing nearshoring, multi-shoring, automation, and digital tracking. It’s about treating medicine like the life-saving resource it is, not just another commodity. The question isn’t whether we can afford to change. It’s whether we can afford not to.Why are most drug ingredients made in China and India?
China and India produce the majority of active pharmaceutical ingredients (APIs) because labor, energy, and regulatory costs are significantly lower than in North America or Europe. Over decades, pharmaceutical companies moved production overseas to cut costs by 60-80%. Today, China supplies over 70% of global APIs, and India handles another 20%, especially for generic drugs. The infrastructure is already built, and switching is expensive and slow.
How do supply chain disruptions cause drug shortages?
Many drugs rely on multiple ingredients, each sourced from different countries. If one key supplier-like a factory in China-shuts down due to labor strikes, weather, or political issues, there’s often no backup. Lead times from Asia to North America have increased by 50% since 2019. Even a two-week delay can empty hospital shelves. In 2024, 60% of drug shortages were directly linked to API supply issues.
Is nearshoring to Mexico a viable solution?
Yes, but it’s not a quick fix. Mexico offers 30-40% lower shipping costs and faster delivery times (under 15 days vs. 45+ from Asia). It’s also part of the USMCA trade deal, making regulations more predictable. However, labor costs are 15-20% higher than in China, and building a new manufacturing plant costs $200 million or more. It takes 18-24 months to get approved and operational.
Why don’t we just make all drugs in Canada or the U.S.?
The infrastructure doesn’t exist at scale. Canada and the U.S. lack the chemical plants, trained chemists, and cost-effective energy needed to replace Asia’s output. Manufacturing labor here is 4.8 times more expensive than in China. Plus, regulatory approval for new facilities takes years. Even if we wanted to reshore everything, it would take over a decade and trillions in investment.
What can governments do to prevent future shortages?
Governments need to treat pharmaceutical supply chains as critical infrastructure. That means funding domestic API production, offering tax breaks for supplier diversification, creating mandatory stockpiles of essential drugs, and speeding up regulatory approvals. Canada’s 2025 National Medicines Strategy is a start, but more coordinated action-like the U.S. CHIPS Act-is needed to make real progress.
14 Comments
It’s wild to think that something as simple as a pill can be held hostage by geopolitical tension. We treat medicine like it’s just another commodity, but it’s not. It’s life support. And yet, we’ve built a system where one port strike in Shanghai can leave a diabetic without insulin. We’re not just outsourcing manufacturing-we’re outsourcing human dignity. And we wonder why people are angry.
It’s not about nationalism. It’s about basic survival. If your child needs an asthma inhaler and the API is stuck in a container ship because of a typhoon, that’s not a supply chain issue. That’s a moral failure. We need to stop pretending this is a business problem. It’s a public health emergency dressed in corporate jargon.
OMG YES. 🙌 I work in a clinic and we had to switch 3 different insulin brands in 2 months last year. Patients were crying. One grandma called me because her vial expired and she couldn’t get a refill. We’re not talking about luxury meds here-we’re talking about people who can’t afford to miss a dose. And the system? Still sleeping. 😴💊
Let’s be real-this is all a CIA plot to control the population. They let China make the drugs so they can flip a switch and cause mass chaos. Think about it: why do you think the FDA approves 90% of Chinese APIs but blocks every domestic startup? It’s not about safety-it’s about control. The same people who run the FDA also own pharmaceutical patents. Coincidence? I think not. 🕵️♂️
India and China are the backbone of global pharma because they’re efficient. The West wants cheap drugs but refuses to pay for the infrastructure to make them. It’s like complaining your car broke down because you didn’t buy a Ferrari. You wanted a Prius. You got a Prius. Stop pretending you didn’t choose this. And yes, I’ve seen the factory reports-India’s API plants have better compliance than most US regional labs. The narrative is lazy.
As someone who grew up in a village in Punjab where our local clinic ran out of antibiotics every monsoon, I can tell you: if it weren’t for Indian generics, millions would’ve died. This isn’t ‘exploitation’-it’s survival. The real tragedy? The West wants the medicine but won’t pay for the dignity of the workers who make it. We treat the pills like magic, but the people who make them like expendable.
Oh, so now we’re going to pretend that bringing manufacturing back to North America is a silver bullet? Let’s pause for a second. The FDA takes 5 years to approve a new API facility. Labor costs are 5x higher. Environmental permits are a Kafkaesque nightmare. And you want to rebuild an entire chemical ecosystem from scratch while the population ages and demand spikes? That’s not policy. That’s delusion wrapped in a PowerPoint.
Meanwhile, Mexico’s doing it right-proximity, USMCA, lower overhead. Why are we ignoring the middle ground? We don’t need to go back to 1980. We need to go forward with intelligence.
It is utterly reprehensible that we have allowed our nation's pharmaceutical sovereignty to be ceded to foreign entities with questionable human rights records and opaque regulatory environments. The fact that our citizens are dependent upon nations that do not share our values for life-sustaining medications is not merely a logistical oversight-it is a catastrophic dereliction of civic duty. One must ask: if a child dies because insulin was delayed by a customs backlog in Mumbai, who bears moral responsibility? The pharmaceutical executives? The policymakers? Or the citizens who voted for complacency? The answer is all of us. And we should be ashamed.
I’ve been in pharmacy for 22 years. I’ve seen shortages come and go. But this? This is different. It’s not just about one factory. It’s about the entire philosophy behind how we value medicine. We treat it like a stock ticker. Buy low, sell high. Don’t worry about the human behind the prescription.
But here’s what I’ve learned: the people who keep the lights on aren’t the CEOs. They’re the lab techs in Hyderabad, the quality control inspectors in Guadalajara, the truck drivers hauling pallets through monsoons. We don’t thank them. We don’t pay them enough. We don’t even know their names.
And yet-they show up. Every day. Even when the system fails them too.
Maybe the fix isn’t just about building more factories. Maybe it’s about finally seeing the people who make the medicine as people. Not costs. Not risks. People.
Let’s be brutally honest: the entire narrative around ‘drug shortages’ is manufactured by fearmongering media and pharma lobbyists trying to extract taxpayer money. There are no true shortages. There are distribution bottlenecks. There are inventory mismanagement issues. There are pharmacies that refuse to stock generics because they make less profit. But no-let’s blame China. Let’s panic. Let’s pass another $1.2 billion bill that ends up in the hands of the same conglomerates who caused the problem in the first place. Classic.
why do we even care about this like its a big deal? people have been getting their meds for decades from india and china. if you cant get your blood pressure pills for a few weeks then maybe you need to get off them? also why is everyone so obsessed with making everything in america? i mean do you want to pay 200$ for a pill that costs 5$? just saying
Here’s the thing nobody’s saying: the future isn’t big factories or national pride-it’s microfactories. Imagine a machine the size of a fridge that can brew 10 different antibiotics on-demand, right inside a hospital. No shipping. No delays. No geopolitical chaos. Just press a button and your drug pops out. It’s already happening. One Canadian startup did it. They’re not waiting for Congress to act. They’re building. And guess what? They’re profitable.
We’re stuck in a 1980s mindset. The next decade of medicine isn’t about borders. It’s about bandwidth. Code. Sensors. AI. And if we keep arguing about who makes the pills, we’ll miss the revolution that’s already in the lab.
Let me just say-this entire post is a classic case of American exceptionalism wrapped in a ‘public health’ blanket. You act like Canada and the U.S. were these moral paragons of pharmaceutical production before outsourcing. Newsflash: we didn’t make the APIs because we were too lazy and too expensive to do it ourselves. We outsourced because we wanted the profit without the pain. Now we’re shocked that the system we designed to maximize ROI has, you know, actual consequences?
And don’t get me started on ‘nearshoring to Mexico’ like that’s some heroic act. Mexico’s labor force is still cheaper than ours. They’re not saving us-they’re just the next cheapest option. We’re not building resilience. We’re just playing musical chairs with exploitation.
And don’t even mention ‘automation.’ You think a $200 million microfactory is going to help a rural clinic in Manitoba? Please. This isn’t innovation. It’s luxury tech for billionaires who want to feel good about their ESG reports.
One must question the motives behind the sudden alarmism regarding pharmaceutical supply chains. The media, academia, and certain political factions have long sought to undermine global trade as a destabilizing force. Now, with the rise of nationalist sentiment and the decline of Western manufacturing, they have seized upon this issue as a convenient vehicle to advance a broader agenda of economic isolationism.
It is not coincidental that this narrative emerges precisely as China’s economic influence expands. The real threat here is not a factory in Shanghai-it is the erosion of rational economic thought. To abandon decades of mutually beneficial globalization over a few temporary disruptions is not wisdom. It is panic dressed as policy.
How quaint. You treat medicine like it’s sacred. It’s not. It’s a product. Like smartphones. Like sneakers. Like coffee. We don’t make all our iPhones in the U.S. We don’t roast all our beans in Seattle. Why should drugs be different? The idea that we need to ‘reclaim’ pharmaceutical sovereignty is the fantasy of people who think economics is a moral test. It’s not. It’s math. And the math says: keep sourcing from the cheapest, most efficient producers.
Stop romanticizing local production. It’s expensive. It’s inefficient. And it will cost lives-through higher prices, not lower supply.